2hon MSN
Vaxart anticipates early 2027 primary efficacy readout while aiming for Q2 sentinel data release
Q1 2026 Management View “In the first quarter, we made meaningful progress advancing our clinical programs and preparing for key data milestones that we believe will help demonstrate the value of our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results